Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) will announce its earnings results before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Persons interested in registering for the company's earnings conference call can do so using this link.
Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last announced its earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.10. The business had revenue of $73.83 million for the quarter, compared to analyst estimates of $51.90 million. On average, analysts expect Esperion Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Esperion Therapeutics Stock Performance
Shares of NASDAQ ESPR traded down $0.09 during mid-day trading on Thursday, reaching $2.04. The company's stock had a trading volume of 2,739,176 shares, compared to its average volume of 6,161,610. The stock has a market capitalization of $386.50 million, a P/E ratio of -2.15 and a beta of 1.00. Esperion Therapeutics has a 1-year low of $0.79 and a 1-year high of $3.40. The stock has a 50-day moving average of $1.86 and a two-hundred day moving average of $2.12.
Wall Street Analysts Forecast Growth
ESPR has been the topic of several recent research reports. HC Wainwright restated a "buy" rating and set a $16.00 target price on shares of Esperion Therapeutics in a report on Wednesday, October 2nd. StockNews.com raised shares of Esperion Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday, October 26th. Finally, Needham & Company LLC decreased their target price on shares of Esperion Therapeutics from $8.00 to $6.00 and set a "buy" rating on the stock in a report on Tuesday, August 13th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat.com, Esperion Therapeutics presently has an average rating of "Hold" and an average target price of $8.17.
Check Out Our Latest Stock Report on ESPR
Esperion Therapeutics Company Profile
(
Get Free Report)
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Recommended Stories
Before you consider Esperion Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Esperion Therapeutics wasn't on the list.
While Esperion Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
